Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026 The trial provided initial safety and tolerability data for Lu AF28996, with most treatment-emergent adverse events reported as mild...
Hence then, the article about lundbeck presents phase ib data for lu af28996 in advanced parkinson s disease as phase ii trial begins was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins )
Also on site :
- Martha Stewart’s Stylish Stoneware Food Container Set Is Perfect for Leftovers, and Just $25 Ahead of Prime Day
- ‘Riverdance’ & ‘Lord of the Dance’ Fans Shocked as Michael Flatley Shares His Wife’s Death at 52: What Happened?
- Neon Sets ‘Artificial’ Oscar Campaign With Andrew Garfield in Supporting Actor, Yura Borisov in Lead (EXCLUSIVE)